Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

20:55 EDT 13 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment has commenced for the first cohort of healthy volunteers ...

Other Sources for this Article

for Prana Biotechnology
Investor Relations
WE Buchan
Rebecca Wilson, +61 47 382 391
WE Buchan
Scott Newstead, +61 3 9866 4722


More From BioPortfolio on "Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases"

Quick Search


Relevant Topics

Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...